Abagovomab Does Not Prolong Progression-Free Survival in Advanced Ovarian Cancer (Mimosa trial)

 WHAT IS THE MIMOSA TRIAL?
MIMOSA is a demanding multinational trial started in December 2006 with a 9 years of duration. About 900 patients with advanced ovarian cancer who have had an optimal response to the initial treatment (surgery + chemotherapy) have been included in the study with the aim to test the efficacy and safety of the vaccination with Abagovomab for the prevention or the delay of disease’s recurrences. The first results will be available at the end of 2010.